Felix Flock

Felix Flock

Auto-generated profile, based on publicly available information

Felix Flock

Department of Gynaecology and Obstetrics, Hospital Memmingen, Memmingen, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2007 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
ZAZiad Atassi
Ziad Atassi
ARAndreas Reich
Andreas Reich
ARAlexandra Rudge
Alexandra Rudge
RKRolf Kreienberg
Rolf Kreienberg
FFFelix Flock
Felix Flock

15 July 2022 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
SSSusanne Singer
Susanne Singer
WJWolfgang Janni
Wolfgang Janni
TKThorsten Kühn
Thorsten Kühn
FFFelix Flock
Felix Flock
RFRicardo Felberbaum
Ricardo Felberbaum
FGfor the BRENDA study group
for the BRENDA study group
Purpose: This study examined the pattern of psychosocial care in breast cancer survivors. Methods: In a prospective study with measurements before surgery, 1 month, 8 months, and 5 years thereafter, we examined the proportion of breast cancer survivors who were aware about, had been offered and received various types of psychosocial services from psychologists, social workers, doctors, self-help groups etc. The degree of helpfulness per service among users was ascertained with Likert scales. Determinants of awareness, offer and use were investigated using binary logistic regression analyses. How the services are inter-related was tested with principal component analyses. Results: Among 456 breast cancer survivors who participated until 5 years, psychological services were known by 91%, offered to 68%, and used by 55% of patients. Social services were known by 86%, offered to 65%, and used by 51%. Women ≥ 65 years were less likely to be informed about (odds ratio (OR) 0.2) and get offers for psychosocial services (OR 0.4 for social and 0.5 for psychological services) than women < 65 years. The services rated most helpful were social services in the hospital, psychological counselling by a consultant and psychotherapy in private practices. Conclusion: These findings underline the importance of psychosocial support by physicians in addition to the "professional" mental health and social care providers. They also show that elderly women in need for support might be in danger of not being well-informed about the services available.

11 May 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
SHSaskia-Laureen Herbert
Saskia-Laureen Herbert
FFFelix Flock
Felix Flock
RFRicardo Felberbaum
Ricardo Felberbaum
WJWolfgang Janni
Wolfgang Janni
SLSanja Löb
Sanja Löb
OGon behalf of the BRENDA Study Group
on behalf of the BRENDA Study Group
Herbert SL, et al. J Breast Cancer. 2023 May;26:e23. https://doi.org/10.4048/jbc.2023.26.e23

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VMVolkmar Mueller
Volkmar Mueller
SLSibylle Loibl
Sibylle Loibl
ELElena Laakmann
Elena Laakmann
DADoris Augustin
Doris Augustin
FFFelix Flock
Felix Flock
IWIsabell Witzel
Isabell Witzel
2070Background: In order to improve knowledge about treatment and outcome of breast cancer patients with brain metastases (BM) we initiated the registry Brain Metastases in Breast Cancer Network Germany (BMBC, GBG79). Methods: Patients diagnosed with BM since 2000 were included retrospectively and prospectively. 1105 patients from 54 centers were analyzed. Results: Median age at diagnosis of BM was 51 years (20 – 87 years). 49.0 % of patients (472/1105) had HER2-pos., 20.5% (198/1005) triple-neg. and 30.5% (294/1005) luminal primary tumors. One year survival rate from diagnosis of BM was 35.7 % (CI95%: 32.6 – 38.8). Median time from first diagnosis of BM to death in the entire cohort was 7.1 month (CI95%: 5.8 – 7.9). HER2-positive patients had the longest median survival with 12.1 mo. (CI95%: 10.2 – 13.7) compared to 5.5 mo. (CI95%: 4.1 – 7.1) for luminal primary tumors and 4.1 mo. (CI95%: 3.1 – 4.8) for triple-negative patients (p < 0.001). Median OS of patients with BM diagnosed between 2000 and 2006 wa...

21 October 2021 in Zeitschrift für Geburtshilfe und Neonatologie
Verified
Journal Article
Closed access
PDF file
SLStefan Lukac
Stefan Lukac
SMSebastian Mayer
Sebastian Mayer
KMKathrin Mühlen
Kathrin Mühlen
FFFelix Flock
Felix Flock
Aim According to the World Health Organization, approximately 810 pregnant women die every day as a consequence of peripartum complications. A large proportion of deaths happen in developing countries. Peripartum cardiac arrest is a rare event that must be treated immediately. It is important to consider the differential diagnoses in order to save lives. Methods In this review, we discuss a differential diagnosis of cardiac arrest according to the BEAU-CHOPS scheme of the American Heart Association in the relation to the case report of our 40-year-old G5/P3 patient who went into cardiac arrest during cesarean delivery. Results Typical differentials for cardiac arrest during labor are bleeding, embolism, anesthetic complications, cardiovascular diseases, eclampsia, and sepsis. All of them were considered and ruled out in this patient. In the end, we suspect that physiological cardio-inhibitory reflexes triggered by sudden profound hypovolemia after placental separation along with the patientʼs risk factors, especially obesity and maternal age, and the administration of spinal anesthesia all potentially contributed to the cardiac arrest. Conclusions This review highlights that the cardiac arrest during labor can be triggered by the multifactorial etiology, but firstly the typical differential diagnosis needs to be excluded. Received: 04 July 2021 Accepted after revision: 13 September 2021 Publication Date: 21 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

28 May 2019 in Senologie - Zeitschrift für Mammadiagnostik und -therapie
Verified
Conference Paper
Closed access
AGA de Gregorio
A de Gregorio
GNG Nagel
G Nagel
TKT Kühn
T Kühn
ARA Rempen
A Rempen
ESE Schlicht
E Schlicht
JHJens Bodo Huober
Jens Bodo Huober
Zielsetzung: Die Kombination aus klassischer Registerstudie mit einer Biomaterialbank sowie einer epidemiologischen Zusatzbefragung wird im Rahmen des BRandO-Bio Projekts für gynäkologische Tumorpatienten der Alb-Allgäu-Bodenseeregion genutzt. Hiermit sollen durch teils wiederholte molekulare Untersuchungen neben Prognose- und Prädiktivmarkern auch Risikopatientinnen mit einer hohen Rezidivwahrscheinlichkeit identifiziert sowie potentielle neue Targets für zielgerichtete Therapien charakterisiert werden. Methoden: Daten von über 3000 Patienten mit neu diagnostiziertem Mamma- oder Ovarialkarzinom, sowie seltenen, malignen Ovarialtumoren oder schwangerschafts-assoziierten Neoplasien der Universitätsfrauenklinik Ulm und der teilnehmenden Netzwerkkliniken in der Alb-Allgäu-Bodenseeregion werden in einer prospektiven Registerstudie dokumentiert. Zudem werden für translationale Forschungsprojekte archiviertes Tumorgewebe sowie wiederholt entnommene Blutproben (zum Zeitpunkt der Erstdiagnose, 1-Jahres Follow-UP sowie bei Rezidiv) asserviert. Hierbei können neben genetischen Analysen am Paraffingewebe auch Analysen von zirkulierender Tumor-DNA sowie Keimbahnuntersuchungen an Zellpellets durchgeführt werden. In ausgewählten Zentren werden den Patienten zusätzlich epidemiologische Fragebögen ausgehändigt. Ergebnisse: Nach einer Pilotphase in Ulm (Studienstart am 01.01.2016) konnten seit 01.03.2017 mit 19 externen Zentren insgesamt 1610 Patienten eingeschlossen werden (Ovarialkarzinome = 77, Mammakarzinome = 1533). Dabei stimmten alle Patienten der Biomaterialasservierung (Blut und Tumor) zu. Blutproben aus externen Zentren waren im Median 2 Tage unterwegs. Die Rücklaufquote der an den beteiligten Zentren (n = 7) ausgegebenen Fragebögen lag bei über 80%. Zusammenfassung: Gynäko-onkologische Patienten der Alb-Allgäu-Bodenseeregion können seit 2016 in das BRandO-Bio-Projekt, einer klassischen prospektiven Registerstudie mit integrierter Biobank sowie einer prospektiven Erhebung von soziodemografischen Faktoren und Lebensstilaspekten mittels epidemiologischer Fragebögen eingeschlossen werden. Durch klinische Analysen und translationale Forschung im Rahmen der BRandO-Bio-Studie soll ein wichtiger Beitrag zur Entwicklung weiterer onkologischer Therapien und Behandlungsstrategien geleistet werden.